Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDF Cardiff Oncology	$3.15 -0.3%	$3.12	$2.01 ▼ $5.64	$209.56M	1.61	1.19 million shs	2.15 million shs
GANX Gain Therapeutics	$1.97 -1.0%	$1.88	$0.89 ▼ $3.19	$58.99M	0.11	295,517 shs	282,966 shs
MDWD MediWound	$19.26 -0.7%	$19.62	$14.14 ▼ $24.00	$208.16M	0.38	87,119 shs	174,715 shs
RZLT Rezolute	$4.35 +0.9%	$3.98	$2.22 ▼ $6.19	$372.01M	1.04	629,654 shs	10.25 million shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDF Cardiff Oncology	-0.32%	+1.61%	-1.25%	-4.26%	+34.62%
GANX Gain Therapeutics	-1.01%	+11.30%	+9.44%	+4.23%	+55.12%
MDWD MediWound	-0.67%	+0.89%	-8.63%	+20.75%	+26.54%
RZLT Rezolute	+0.93%	+5.84%	+10.13%	+48.46%	+8.75%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRDF Cardiff Oncology	1.6342 of 5 stars	3.4	1.0	2.7	0.0	0.6
GANX Gain Therapeutics	3.2285 of 5 stars	3.6	5.0	3.6	0.0	0.6
MDWD MediWound	1.8141 of 5 stars	3.5	1.0	2.2	0.8	0.6
RZLT Rezolute	3.1023 of 5 stars	3.6	1.0	4.2	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRDF Cardiff Oncology	2.80	Moderate Buy	$9.88	213.49% Upside
GANX Gain Therapeutics	3.17	Buy	$8.20	316.24% Upside
MDWD MediWound	3.00	Buy	$31.80	65.11% Upside
RZLT Rezolute	3.14	Buy	$11.83	172.03% Upside

Current Analyst Ratings Breakdown

Latest GANX, MDWD, RZLT, and CRDF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	CRDF Cardiff Oncology	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$3.50
6/18/2025	CRDF Cardiff Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/2/2025	MDWD MediWound	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$34.00
5/22/2025	MDWD MediWound	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$25.00 ➝ $31.00
5/19/2025	GANX Gain Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
5/14/2025	RZLT Rezolute	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$12.00
5/9/2025	CRDF Cardiff Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$17.00 ➝ $18.00
5/2/2025	MDWD MediWound	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
4/28/2025	RZLT Rezolute	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
3/28/2025	GANX Gain Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRDF Cardiff Oncology	$680K	308.19	N/A	N/A	$1.86 per share	1.69
GANX Gain Therapeutics	$50K	1,180.03	N/A	N/A	$0.28 per share	7.04
MDWD MediWound	$20.22M	10.30	N/A	N/A	$2.89 per share	6.66
RZLT Rezolute	N/A	N/A	N/A	N/A	$2.19 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRDF Cardiff Oncology	-$45.43M	-$0.92	N/A	N/A	N/A	-8,308.50%	-76.45%	-62.85%	8/14/2025 (Estimated)
GANX Gain Therapeutics	-$20.41M	-$0.86	N/A	N/A	N/A	N/A	-247.55%	-146.06%	8/6/2025 (Estimated)
MDWD MediWound	-$30.22M	-$2.09	N/A	N/A	N/A	-110.45%	-74.12%	-30.92%	8/13/2025 (Estimated)
RZLT Rezolute	-$68.46M	-$1.15	N/A	N/A	N/A	N/A	-70.09%	-63.08%	N/A

Latest GANX, MDWD, RZLT, and CRDF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	MDWD MediWound	-$0.65	-$0.07	+$0.58	-$0.07	$5.20 million	$3.96 million
5/14/2025	Q1 2025	GANX Gain Therapeutics	-$0.16	-$0.16	N/A	-$0.16	$0.03 million	N/A
5/13/2025	Q3 2025	RZLT Rezolute	-$0.22	-$0.27	-$0.05	-$0.27	N/A	N/A
5/8/2025	Q1 2025	CRDF Cardiff Oncology	-$0.19	-$0.20	-$0.01	-$0.20	$0.09 million	$0.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
GANX Gain Therapeutics	N/A	N/A	N/A	N/A	N/A
MDWD MediWound	N/A	N/A	N/A	N/A	N/A
RZLT Rezolute	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRDF Cardiff Oncology	N/A	6.22	6.22
GANX Gain Therapeutics	0.05	2.22	2.22
MDWD MediWound	N/A	2.15	1.99
RZLT Rezolute	N/A	8.43	8.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRDF Cardiff Oncology	16.29%
GANX Gain Therapeutics	11.97%
MDWD MediWound	46.83%
RZLT Rezolute	82.97%

Insider Ownership

Company	Insider Ownership
CRDF Cardiff Oncology	7.70%
GANX Gain Therapeutics	7.18%
MDWD MediWound	9.20%
RZLT Rezolute	18.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRDF Cardiff Oncology	20	66.53 million	61.40 million	Optionable
GANX Gain Therapeutics	20	29.95 million	27.80 million	Optionable
MDWD MediWound	80	10.81 million	9.81 million	Optionable
RZLT Rezolute	40	85.52 million	69.79 million	Optionable

GANX, MDWD, RZLT, and CRDF Headlines

Recent News About These Companies

Brian Kenneth Roberts Buys 2,500 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock

June 27 at 7:49 AM | insidertrades.com

Insider Buying: Rezolute, Inc. (NASDAQ:RZLT) Insider Buys 2,500 Shares of Stock

June 26 at 11:25 AM | marketbeat.com

Insider Buying: Rezolute, Inc. (NASDAQ:RZLT) Director Acquires 1,230,769 Shares of Stock

June 26 at 4:23 AM | americanbankingnews.com

Insider Buying: Rezolute, Inc. (NASDAQ:RZLT) CFO Buys 5,000 Shares of Stock

June 25 at 5:56 AM | insidertrades.com

Rezolute, Inc. (NASDAQ:RZLT) CFO Acquires $20,250.00 in Stock

June 24, 2025 | marketbeat.com

Young-Jin Kim Buys 1,230,769 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock

June 24, 2025 | insidertrades.com

Young-Jin Kim Acquires 1,230,769 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock

June 23, 2025 | marketbeat.com

Contrasting Aadi Bioscience (NASDAQ:AADI) and Rezolute (NASDAQ:RZLT)

June 19, 2025 | americanbankingnews.com

Rezolute, Inc. (NASDAQ:RZLT) Receives Consensus Recommendation of "Buy" from Analysts

June 14, 2025 | marketbeat.com

Bank of America Corp DE Has $443,000 Stock Position in Rezolute, Inc. (NASDAQ:RZLT)

June 12, 2025 | marketbeat.com

69,724 Shares in Rezolute, Inc. (NASDAQ:RZLT) Bought by Ameriprise Financial Inc.

June 6, 2025 | marketbeat.com

Rezolute, Inc. (NASDAQ:RZLT) is a favorite amongst institutional investors who own 77%

June 3, 2025 | finance.yahoo.com

Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism

May 28, 2025 | globenewswire.com

Man Group plc Makes New $425,000 Investment in Rezolute, Inc. (NASDAQ:RZLT)

May 28, 2025 | marketbeat.com

Rezolute, Inc.: Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

May 21, 2025 | finanznachrichten.de

Rezolute, Inc. (RZLT): Analysts See 260% Upside Potential

May 20, 2025 | finance.yahoo.com

Rezolute, Inc. Reports Progress on sunRIZE Enrollment and Breakthrough Therapy Designation for Ersodetug in Hypoglycemia Treatment

May 15, 2025 | nasdaq.com

Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

May 13, 2025 | globenewswire.com

FDA grants breakthrough status to Rezolute’s hypoglycemia therapy

May 6, 2025 | investing.com

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

May 5, 2025 | globenewswire.com

Rezolute to Participate in Upcoming Investor Conferences

May 1, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GANX, MDWD, RZLT, and CRDF Company Descriptions

Cardiff Oncology NASDAQ:CRDF

$3.15 -0.01 (-0.32%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$3.20 +0.06 (+1.75%)

As of 06/27/2025 07:56 PM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Gain Therapeutics NASDAQ:GANX

$1.97 -0.02 (-1.01%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.96 0.00 (-0.25%)

As of 06/27/2025 07:32 PM Eastern

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

MediWound NASDAQ:MDWD

$19.26 -0.13 (-0.67%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$19.28 +0.02 (+0.10%)

As of 06/27/2025 04:34 PM Eastern

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Rezolute NASDAQ:RZLT

$4.35 +0.04 (+0.93%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.38 +0.04 (+0.80%)

As of 06/27/2025 07:59 PM Eastern

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time